Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

Importin 9 anticorps (AA 158-176)

IPO9 Reactivité: Humain WB, ELISA, IHC Hôte: Lapin Polyclonal unconjugated
N° du produit ABIN7140094
  • Antigène Voir toutes Importin 9 (IPO9) Anticorps
    Importin 9 (IPO9)
    Épitope
    • 15
    • 8
    • 7
    • 6
    • 5
    • 3
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 158-176
    Reactivité
    • 48
    • 36
    • 5
    • 3
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Humain
    Hôte
    • 57
    • 5
    • 1
    Lapin
    Clonalité
    • 55
    • 8
    Polyclonal
    Conjugué
    • 30
    • 4
    • 4
    • 4
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    Cet anticorp Importin 9 est non-conjugé
    Application
    • 53
    • 22
    • 18
    • 14
    • 13
    • 13
    • 10
    • 6
    • 4
    • 3
    • 3
    • 1
    • 1
    • 1
    Western Blotting (WB), ELISA, Immunohistochemistry (IHC)
     Réactivité croisée
    Humain
    Purification
    Antigen Affinity Purified
    Immunogène
    Peptide sequence from Human Ran-binding protein 9 protein (158-176AA)
    Isotype
    IgG
    Top Product
    Discover our top product IPO9 Anticorps primaire
  • Indications d'application
    Recommended dilution: WB:1:500-1:2000, IHC:1:20-1:200,
    Restrictions
    For Research Use only
  • Format
    Liquid
    Buffer
    Preservative: 0.03 % Proclin 300
    Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4
    Agent conservateur
    ProClin
    Précaution d'utilisation
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Stock
    -20 °C,-80 °C
    Stockage commentaire
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • Antigène
    Importin 9 (IPO9)
    Autre désignation
    RANBP9 (IPO9 Produits)
    Synonymes
    anticorps Imp9, anticorps 0710008K06Rik, anticorps AI845704, anticorps C78347, anticorps Ranbp9, anticorps mKIAA1192, anticorps zgc:66429, anticorps wu:fc23d12, anticorps MGC81741, anticorps IPO9, anticorps DDBDRAFT_0205722, anticorps DDBDRAFT_0229883, anticorps DDB_0205722, anticorps DDB_0229883, anticorps RGD1561940, anticorps RanBPM, anticorps RanBP9, anticorps bpm-l, anticorps bpm90, anticorps ranbp9, anticorps ranbp9-a, anticorps ranbp9-b, anticorps ranbp9b, anticorps cb457, anticorps zgc:158650, anticorps importin 9, anticorps importin 9 L homeolog, anticorps RAN binding protein 9, anticorps RAN binding protein 9 L homeolog, anticorps IPO9, anticorps Ipo9, anticorps ipo9, anticorps ipo9.L, anticorps cnrP, anticorps Ranbp9, anticorps ranbp9.L, anticorps RANBP9, anticorps ranbp9
    Sujet

    Background: May act as an adapter protein to couple membrane receptors to intracellular signaling pathways. May be involved in signaling of ITGB2/LFA-1 and other integrins. Enhances HGF-MET signaling by recruiting Sos and activating the Ras pathway. Enhances dihydrotestosterone-induced transactivation activity of AR, as well as dexamethasone-induced transactivation activity of NR3C1, but not affect estrogen-induced transactivation. Stabilizes TP73 isoform Alpha, probably by inhibiting its ubiquitination, and increases its proapoptotic activity. Inhibits the kinase activity of DYRK1A and DYRK1B. Inhibits FMR1 binding to RNA (By similarity).

    Aliases: B cell antigen receptor Ig beta associated protein 1 antibody, BPM 90 antibody, BPM L antibody, BPM-L antibody, BPM90 antibody, BPML antibody, IBAP 1 antibody, Imp 9 antibody, Importin 9 antibody, Novel centrosomal protein RanBPM antibody, RAN binding protein 9 antibody, Ran binding protein centrosomal antibody, Ran Binding Protein in the Microtubule organizing center antibody, Ran binding protein M antibody, Ran BP9 antibody, Ran-binding protein 9 antibody, Ran-binding protein M antibody, RANB9_HUMAN antibody, RanBP 7 antibody, RANBP 9 antibody, RanBP7 antibody, RanBP9 antibody, RanBPM antibody

    UniProt
    Q96S59
    Pathways
    Protein targeting to Nucleus
Vous êtes ici: